Veracyte Buys Convergent Genomics to Add Urinary Tumor DNA Testing
VCYT sits 40% above its 52-week low of $29.455.
Summary
Veracyte is acquiring Convergent Genomics, a move that adds a urinary tumor DNA testing platform to its urology diagnostics portfolio and expands its presence in this key growth area. The deal, valued at $150 million in upfront cash with up to an additional $30 million tied to key milestones, complements Veracyte's existing Decipher Prostate test and is expected to enhance its ability to detect and monitor bladder cancer. Veracyte has already contemplated Convergent's operating expenses in its 2026 adjusted EBITDA guidance and is not updating that guidance at this time. This strategic acquisition follows a strong second quarter for Veracyte, where revenue rose 15% to $150.3 million, leading the company to raise its full-year guidance.
At the time of this announcement, VCYT was trading at $41.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.3B. The 52-week trading range was $29.46 to $60.91. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.